Opinion|Videos|January 24, 2025
Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitor selection in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) depends on key factors including prior therapy response, BTK C481 mutation status, comorbidities, drug interaction profiles, dosing convenience, and adverse effect considerations, with noncovalent inhibitors offering particular benefit for those with BTK mutations or intolerance to covalent agents.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What key factors influence your decision when selecting among the available BTK inhibitors for patients with R/R CLL?
- What clinical or molecular features help identify patients with R/R CLL who are most likely to benefit from noncovalent BTK inhibitors compared with covalent BTK inhibitors?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
Kerry Rogers, MD, on BTK Inhibitor Selection and Tolerability in CLL
3
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
4
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
5